RNA N6-Methyladenosine Pathway Writer Genes Expression Levels and Clinical Severity of Infection in Covid-19 Patients
View/ Open
Date
12.09.2023Author
arslan badelbaltacı sevgi
tüzemen bayyurt elif burcu
özbilüm şahin nil
akyürek murat eser
bakır mehmet
Metadata
Show full item recordAbstract
Epigenetic modifications are known to be effective in the severity and mortality rate of SARS-CoV-2 infection. N6-methyladenosin (m6A) is a posttranscriptional modification that is carried out by m6A methyltransferases (METTL3, METTL14, and WTAP). This modification is effective in the formation of a natural immune response in the relationship between the viral genome and the host cell. In this study, the relationship between clinical severity and METTL3, METTL14, WTAP expression levels in Covid-19 patients was studied for the first time. Also, patients’ D-dimer, ferritin, and C-reactive protein values were compared with these gene expression levels. Total RNA was extracted from blood samples of 100 volunteers and gene expressions were measured using a quantitative real-time polymerase chain reaction. It was determined that METTL3 (p < 0.001) and METTL14 (p = 0.005) genes were statistically significant between case and control. In addition, METTL14 (p = 0.007) and WTAP (p = 0.015) gene expressions were significantly increased in patients with severe disease. METTL14 was statistically significant between the male patients and the control (fold change = 63.87, p = 0.015). Overexpression of the METTL14 gene may have resulted in higher clinical severity in males. Our results demonstrate that host N6-methyladenosine (m6A) methyltransferases may be effective in the development of SARS-CoV-2 infection and prognosis of the disease.